| 摘要 |
The present invention relates to a compound of formula (I) wherein R1 is hydrogen or lower alkyl; R2 is lower alkyl, lower hydroxyalkyl or -(CHR5)x-A ; R5 is hydrogen, lower alkyl or lower hydroxyalkyl, or is heteroaryl option ally substituted by lower alkyl; A is cycloalkyl, aryl, heterocyclyl or hete roaryl, which rings are optionally substituted one or more R6, wherein R6 is lower alkyl, lower alkoxy, lower alkylsulfonyl, cyano, halogen, lower alkyl substituted by halogen or lower alkoxy substituted by halogen, or is aryl, heterocyclyl or heteroaryl optionally substituted by lower alkyl or is cyclo alkyl optionally substituted by lower alkyl; x is 0, 1, 2 or 3; or R1, R2 ma y form together with the N-atom heterocyclyl or heteroaryl, which rings are optionally substituted by one or more substituents selected from the group c onsisting of lower alkyl, lower alkoxy, lower alkylsulfonyl, halogen, cycloa lkyl, benzyl or aryl; R3 is hydrogen or halogen; R4 is hydrogen or lower alk yl; R7 is hydrogen, halogen or lower alkyl; m is 1 or 2; when m is 2, R3 may be the same or not; n is 1 or 2; o is 1 or 2; when o is 2, R7 may be the sa me or not; or to a pharmaceutically suitable acid addition salt thereof. It has been found that the present compounds are high potential NK-3 receptor a ntagonists for the treatment of depression, pain, psychosis, Parkinson's dis ease, schizophrenia, anxiety and attention deficit hyperactivity disorder (A DHD).
|
